Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 77

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 77
---
 diseases, including rare or orphan diseases. While we
believe our efforts can result in commercial success, if our estimates of the target patient populations are too optimistic, if the target
patient population is relatively small, or if our drug candidates do not address the entire target patient population of a rare disease
for example, such drug candidates may not generate significant product revenue and could adversely affect our financial position and our
stock price.

Our subsidiaries may become a party to certain agreements that
provide our licensors, collaborators or other stockholders in our subsidiaries with rights that could delay or impact the potential sale
of our subsidiaries or could impact the ability of our subsidiaries to sell assets, or enter into strategic alliances, collaborations
or licensing arrangements with other third parties.

Our subsidiaries may directly or indirectly license intellectual property
from third parties and may be partially or majority owned by third party investors. These third parties may have certain rights that could
delay collaboration, licensing or other arrangements with another third party, and the existence of these rights may adversely impact
the ability to attract an acquirer or partner.

We may form additional subsidiaries and enter into similar agreements
with future partners or investors, or our subsidiaries may enter into further agreements, that in each case may contain similar provisions
or other terms that are not favorable to us.

Although we currently own 100% of our subsidiaries (i.e., there
are no third-party, minority investors), we may, in the future, acquire companies that have minority shareholders or we may make
investments where we are a minority shareholder. Where we are the majority shareholder, we will have certain duties to minority shareholders,
which may limit our ability to integrate operations with our other subsidiaries. If we make an investment as a minority investor, we are
unlikely to exert much, if any, control over the business and we may be limited in our ability to realize value from those investments.

We currently own wholly-owned subsidiaries, and plan to be the
majority owner of future subsidiaries. In the event that we acquire a majority ownership interest or make an investment in another company,
or if any of our subsidiaries require additional capital and such additional capital is obtained from third party investors rather than
from us, we may be (or may become) a minority shareholder and unable to control the business and operations of those companies.

If the companies in which we are a minority shareholder conduct their
business in a manner detrimental to our interests, business, or reputation, our returns may be adversely affected. Companies in which
we